Century Therapeutics (IPSC) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Platform differentiation and technology

• Focus on iPSC-derived cell therapies with integrated protein, cell, and genetic engineering, plus in-house manufacturing.

• Key differentiators: engineerability, reproducibility, and profitable scalability, enabling unlimited gene editing and large batch production.

• Ability to generate multiple immune effector cell types, including NK, gamma delta T, and alpha beta T cells.

• Allo-Evasion technology enables engineered cells to coexist with patient immune systems, allowing repeat dosing and improved durability.

CNTY-101 program and Allo-Evasion strategy

• CNTY-101 features six precision gene edits, three for Allo-Evasion, including HLA removal and HLA-E expression to avoid immune rejection.

• Allo-Evasion iterations (1.0, 3.0, 5.0) progressively enhance protection against T, NK, and humoral immune responses.

• Allo-Evasion enables persistence of cell therapies with or without lymphodepletion, as shown in recent data.

Clinical data and trial updates

• Phase 1 ELiPSE trial in relapsed/refractory non-Hodgkin's lymphoma: 20 patients for safety, 19 for efficacy, with severe, heavily pretreated cases.

• Favorable safety profile: no GVHD, no dose-limiting toxicities, mostly low-grade, transient CRS and ICANS, and outpatient treatment possible.

• Efficacy: 83% response rate at higher dose (3B cohort), including complete responses, especially in patients with prior CAR-T.

• Translational data show persistent cell exposure, proof of Allo-Evasion, deep B-cell depletion, and B-cell reset profiles linked to durable remission.

• Dose escalation to 4B underway, with focus on safety, deeper responses, and durability at higher doses.